Table 1 Individual demographic data and clinical features of patients of LDLT who underwent RYHJ
Recipient age (years) | Gender | MELD score | Cold ischemia time (min) | Warm ischemia time (min) | Anhepatic phase time(min) | RL-LDLT operative time (min) | RL-LDLT blood loss (ml) | RYHJ operative time (min) | RYHJ blood loss (ml) | Time from RL-LDLT to RYHJ (month) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 51 | Male | 6 | 114 | 1 | 45 | 390 | 1500 | 270 | 250 | 49.5 |
2 | 47 | Male | 13 | 155 | 1 | 29 | 420 | 700 | 250 | 250 | 48 |
3 | 50 | Male | 13 | 145 | 38 | 49 | 540 | 3800 | 195 | 300 | 60.5 |
4 | 60 | Male | 19 | 29 | 23 | 88 | 390 | 4400 | 325 | 650 | 30 |
5 | 56 | Male | 16 | 64 | 22 | 100 | 370 | 6000 | 290 | 1750 | 18 |
6 | 50 | Male | 22 | 95 | 25 | 32 | 360 | 7000 | 195 | 150 | 46.5 |
7 | 58 | Male | 13 | 113 | 34 | 49 | 330 | 3650 | 275 | 300 | 19.5 |
8 | 58 | Female | 27 | 103 | 20 | 27 | 390 | 1400 | 245 | 250 | 31 |
9 | 47 | Male | 9 | 83 | 15 | 18 | 315 | 800 | 265 | 350 | 16 |
10 | 59 | Female | 11 | 90 | 25 | 26 | 360 | 1100 | 220 | 100 | 27.5 |
11 | 65 | Male | 7 | 66 | 21 | 22 | 345 | 600 | 325 | 300 | 14.5 |
12 | 60 | Female | 11 | 55 | 24 | 31 | 365 | 3000 | 240 | 650 | 11.5 |
13 | 47 | Male | 25 | 92 | 18 | 28 | 180 | 7000 | 255 | 250 | 24 |
14 | 53 | Male | 17 | 66 | 24 | 25 | 435 | 2300 | 240 | 100 | 10 |
15 | 49 | Male | 9 | 86 | 14 | 15 | 250 | 1000 | 215 | 100 | 10.5 |
16 | 50 | Male | 10 | 55 | 17 | 26 | 260 | 1500 | 530 | 500 | 5 |
17 | 45 | Male | 20 | 35 | 18 | 15 | 370 | 3000 | 225 | 300 | 12 |
18 | 52 | Male | 9 | 44 | 17 | 64 | 335 | 8000 | 270 | 550 | 6 |
19 | 45 | Male | 28 | 64 | 17 | 19 | 320 | 3500 | 365 | 1500 | 2.5 |
20 | 71 | Male | 13 | 114 | 15 | 28 | 310 | 5000 | 445 | 1700 | 3.5 |
21 | 46 | Male | 7 | 114 | 15 | 28 | 390 | 800 | 180 | 100 | 0.3 |
22 | 39 | Female | 24 | 23 | 15 | 18 | 280 | 2200 | 280 | 7000 | 1.5 |
Bile leak | Bile duct anastomosis orifice no | Type of bile duct anastomosis | T-Tube placement | Hepatic artery complications | IHD stone formation | ABO incompatibility | Rejection | Survival | Hospital Mortality | |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Yes | 2 | D-D | No | No | Yes | No | Yes | Yes | No |
2 | Yes | 2 | D-D | No | No | Yes | No | No | No | No |
3 | Yes | 1 | D-D | Yes | No | Yes | No | Yes | Yes | No |
4 | No | 1 | D-G | Yes | No | Yes | No | No | Yes | No |
5 | Yes | 3 | D-G | No | No | Yes | No | No | No | No |
6 | No | 1 | D-G | No | No | Yes | No | Yes | Yes | No |
7 | No | 1 | D-G | No | No | Yes | No | No | No | No |
8 | No | 2 | D-G | No | No | Yes | Yes | Yes | Yes | No |
9 | No | 1 | D-G | No | Yes | Yes | No | No | Yes | No |
10 | No | 2 | D-G | No | No | Yes | Yes | No | Yes | No |
11 | No | 2 | D-G | No | No | No | No | No | Yes | No |
12 | No | 1 | D-G | No | No | Yes | No | No | No | No |
13 | Yes | 1 | D-G | Yes | Yes | Yes | No | No | No | No |
14 | No | 1 | D-G | No | Yes | Yes | No | No | Yes | No |
15 | No | 1 | D-G | No | No | No | No | Yes | Yes | No |
16 | No | 1 | D-D | Yes | No | Yes | Yes | Yes | No | Yes |
17 | No | 1 | D-D | No | No | No | Yes | No | Yes | No |
18 | Yes | 1 | D-D | Yes | No | No | No | Yes | Yes | No |
19 | Yes | 1 | D-D | No | No | No | No | No | Yes | No |
20 | Yes | 1 | D-D | No | No | No | No | No | No | Yes |
21 | Yes | 2 | D-D | No | No | No | No | No | Yes | No |
22 | Yes | 2 | D-D | No | No | No | No | Yes | No | Yes |